Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide O...( Companies Committed to Investing in N...),Health

Companies Committed to Investing in New Product Presentations for Patients

SAN DIEGO and INDIANAPOLIS, April 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the companies have agreed in principle to the terms of a joint supply agreement for an exenatide once weekly pen device. Separately, the companies announced that they have initiated a phase 1/2 clinical study to examine a new exenatide once weekly suspension formulation.

Exenatide once weekly is an investigational diabetes therapy that is injected subcutaneously once a week and is currently in phase 3 development. Exenatide is also the active ingredient in twice daily BYETTA(R) (exenatide) injection, currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic control with common oral therapies.

Exenatide Once Weekly Pen Supply Agreement

Amylin and Lilly have agreed in principle to cooperate in the development, manufacturing and marketing of exenatide once weekly in a dual chamber cartridge pen configuration. This design will enable patients to mix and administer exenatide once weekly from a pre-filled pen device, instead of the syringe and vial currently used in clinical trials. The companies will share the capital and development costs of the pen, including the initial capital investment of approximately $216 million over the next few years. Amylin and Lilly have agreed that the cost of the initial capital investment will be allocated 60 percent to Lilly and 40 percent to Amylin.

Amylin will be responsible for developing and manufacturing the final pen product for the U.S., an
'/>"/>